TY - JOUR
T1 - Result of phase II clinical trial of herceptin in advanced Chinese breast cancer patients
AU - Sun, Yan
AU - Li, Li qing
AU - Song, San tai
AU - Xu, Li gong
AU - Yu, Shi ying
AU - Wang, Jin wan
AU - Jiang, Ze fei
AU - Yin, Ji liang
AU - Xiong, Hui hua
PY - 2003/11
Y1 - 2003/11
N2 - OBJECTIVE: To observe the clinical efficacy and adverse effects of herceptin for advanced Chinese breast cancer patients. METHODS: Thirty-one pathologically proved advanced breast cancer women were treated by herceptin. In the first week, a loading dose 4 mg/kg was administered by intravenous infusion and from the second week, a routine dose of 2 mg/kg was given every week for at least 3 months. RESULTS: There were 2 CR, 6 PR, 7 SD, and 16 PD among 31 patients after treatment by herceptin, the response rate being 25.8%. In factors influencing the prognosis, age and general condition were factors favoring the results, and pathological type, site of metastasis, grade of her-2 over expression and prior treatment were irrelevant to the results. The adverse effects were mild but different from those of the common anticancer drugs. CONCLUSION: Herceptin is effective and well tolerated by the Chinese breast cancer patients.
AB - OBJECTIVE: To observe the clinical efficacy and adverse effects of herceptin for advanced Chinese breast cancer patients. METHODS: Thirty-one pathologically proved advanced breast cancer women were treated by herceptin. In the first week, a loading dose 4 mg/kg was administered by intravenous infusion and from the second week, a routine dose of 2 mg/kg was given every week for at least 3 months. RESULTS: There were 2 CR, 6 PR, 7 SD, and 16 PD among 31 patients after treatment by herceptin, the response rate being 25.8%. In factors influencing the prognosis, age and general condition were factors favoring the results, and pathological type, site of metastasis, grade of her-2 over expression and prior treatment were irrelevant to the results. The adverse effects were mild but different from those of the common anticancer drugs. CONCLUSION: Herceptin is effective and well tolerated by the Chinese breast cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=2142743346&partnerID=8YFLogxK
M3 - Article
C2 - 14690567
AN - SCOPUS:2142743346
VL - 25
SP - 581
EP - 583
JO - Zhonghua zhong liu za zhi [Chinese journal of oncology]
JF - Zhonghua zhong liu za zhi [Chinese journal of oncology]
SN - 0253-3766
IS - 6
ER -